Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Bartoletti

Showing results (51-60 of 55) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 55 results.
The Journal of Urology|January 1, 1993
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trialR A Janknegt, C C Abbou, R Bartoletti, et al.
Urologia Internationalis|August 30, 2014
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcomeM Racioppi, L Salmaso, C Brombin, et al.
Actas Urologicas Espanolas|June 20, 2021
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patientsF Pisano, P Gontero, R Sylvester, et al.
World Journal of Urology|May 4, 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thoughtJ Palou, F Pisano, R Sylvester, et al.
World Journal of Urology|September 2, 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomyFrancesco Soria, Francesca Pisano, Paolo Gontero, et al.
Pageof 6

Showing results (51-60 of 55) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 55 results.
The Journal of Urology|January 1, 1993
Orchiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind randomized trialR A Janknegt, C C Abbou, R Bartoletti, et al.
Urologia Internationalis|August 30, 2014
The clinical use of statistical permutation test methodology: a tool for identifying predictive variables of outcomeM Racioppi, L Salmaso, C Brombin, et al.
Actas Urologicas Espanolas|June 20, 2021
Risk factors for residual disease at re-TUR in a large cohort of T1G3 patientsF Pisano, P Gontero, R Sylvester, et al.
World Journal of Urology|May 4, 2018
Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thoughtJ Palou, F Pisano, R Sylvester, et al.
World Journal of Urology|September 2, 2018
Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomyFrancesco Soria, Francesca Pisano, Paolo Gontero, et al.
Pageof 6